Phaseline

Targets › CSPG4

CSPG4 (Chondroitin sulfate proteoglycan 4): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2027.

Proteoglycan playing a role in cell proliferation and migration which stimulates endothelial cells motility during microvascular morphogenesis. May also inhibit neurite outgrowth and growth cone collapse during axon regeneration. (UniProt, Q6UVK1)

Open in Phaseline: the race on CSPG4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Beijing BiotechEB-DTKN-401
Dual-target CSPG4/GD2 CAR-NK cells
CSPG4, GD2Phase 1Unresectable MelanomaJun 2027

Conditions

Unresectable Melanoma (1)

Modalities

mixed (1)

Companies

Beijing Biotech (1)

Related targets

GD2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.